Proposal to list Interventional Radiology products supplied by Endotherapeutics New Zealand Limited, Terumo Australia Pty Limited and Boston Scientific New Zealand Limited
What we’re proposing
PHARMAC is seeking feedback on a proposal to list a range of Interventional Radiology Products in Part III of Section H of the Pharmaceutical Schedule from 1 September 2018 through a provisional agreement with Endotherapeutics New Zealand Limited (trading as Endoventure) (“Endoventure”), Terumo Australia PTY Limited (“Terumo”) and Boston Scientific New Zealand Limited (“Boston”).
Consultation closes at 5pm on Friday, 20 July 2018 and feedback can be emailed to email@example.com.
What would the effect be?
From 1 September 2018, Endoventure’s, Terumo’s and Boston’s ranges of interventional radiology products would fall under proposed national agreements (“Agreements”) that all DHBs may purchase under. The Agreements provide national consistency for these devices as the Price and Terms & Conditions stated in the Agreements apply to all DHB purchases from the date of listing on the Pharmaceutical Schedule.
The Agreements would not be for sole supply, with DHBs continuing to be able to purchase other suppliers’ brands of interventional radiology products.
These Agreements would supersede any existing DHB contract with the supplier for the devices listed in the Schedule 1 of the Agreements. Any device listed in a PHARMAC Agreement and purchased by a DHB would be at the Price, Terms and Conditions stated in the Agreements, effective from the date of listing on the Pharmaceutical Schedule.
PHARMAC estimates that the Endoventure agreement would result in a small cost increase to DHBs of $7,000 per annum, based on current usage.
PHARMAC estimates that the Terumo agreement would result in a small saving to DHBs of $4,000 per annum, based on current usage.
PHARMAC estimates that the Boston agreement would offer national savings to DHBs of $202,000 per annum, based on current usage.
Who we think will be interested
- Suppliers and Wholesalers
- DHB Staff
- Interventional Radiology staff
- Procurement officers
About Interventional Radiology products
Interventional radiology refers to a range of minimally invasive alternatives to surgery to diagnose and treat a variety of conditions in nearly every organ system, that are performed using radiologic imaging guidance to precisely target the intervention. The procedures are performed using catheters inserted via either radial or femoral arteries or veins.
The imaging modalities used include general radiography including fluoroscopy, angiography, ultrasound, computed tomography, and magnetic resonance imaging.
Interventional radiology in some form is performed in all hospitals across New Zealand.
Why we’re proposing this
In September 2017 PHARMAC issued a Request for Proposals for interventional radiology products. The RFP was for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
PHARMAC has been working with suppliers in order to seek provisional agreements and this is the first proposal to arise from that process. We intend to consult on proposed agreements with other suppliers over the next few months.
Details about our proposal
PHARMAC has entered into provisional Agreements with Endoventure, Terumo and Boston for a range of interventional radiology products. The exact product ranges and pricing in these proposals have not been included in this consultation for brevity but includes accessories and specialist procedure packs. We are making the full list available to Procurement Departments at DHBs. Manufacturer’s ranges and product brands in the agreement are summarised below:
Terumo Medical Corporation
Boston Scientific Corporation
To provide feedback
Send us an email: firstname.lastname@example.org by Friday 20 July 2018.
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.
Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.
We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.